Skip to main content
Year archive

CLINUVEL PHARMACEUTICALS LIMITED — 2016 filings

All 52 regulatory filings released by CLINUVEL PHARMACEUTICALS LIMITED (CUV) in 2016, sourced directly from the official regulator.

52 Filings
2016 Period
2016 filings (52)
Filing Released Lang
Change of Director's Interest Notice 2 pages 674.2KB
Director's Dealing
2016-12-22 English
CLINUVEL Newsletter 4 pages 782.1KB
Management Reports
2016-12-19 English
Change of Director's Interest Notice 2 pages 674.0KB
Director's Dealing
2016-12-12 English
Chairman's Address to Shareholders 2 pages 101.3KB
AGM Information
2016-11-27 English
Managing Director AGM Presentation 28 pages 1.9MB
AGM Information
2016-11-27 English
Results of Meeting 3 pages 104.5KB
Declaration of Voting Results & Voting Rights Announcements
2016-11-27 English
CLINUVEL agrees with FDA on New Drug Application timelines 2 pages 546.8KB
Regulatory Filings
2016-11-08 English
Appendix 4C - quarterly 5 pages 328.5KB
Interim / Quarterly Report
2016-10-30 English
Response to ASX Price Query 4 pages 1.0MB
Regulatory Filings
2016-10-30 English
Notice of Annual General Meeting/Proxy Form 10 pages 444.1KB
AGM Information
2016-10-26 English
Appendix 4G and Corporate Governance Statement 17 pages 928.5KB
Governance Information
2016-10-26 English
Annual Report to shareholders 54 pages 1.5MB
Regulatory Filings
2016-10-26 English
FDA erythropoietic protoporphyria (EPP) scientific workshop 2 pages 342.1KB
Regulatory Filings
2016-10-23 English
CLINUVEL Relocates Melbourne Office 1 page 334.8KB
Regulatory Filings
2016-10-23 English
SCENESSE - NICE England Update 2 pages 286.7KB
Regulatory Filings
2016-10-17 English
FDA Schedules Pre-NDA Meeting for SCENESSE 3 pages 521.5KB
Regulatory Filings
2016-10-12 English
Media Release-CLINUVEL to discuss SCENESSE at PreNDA Meeting 2 pages 351.3KB
Regulatory Filings
2016-10-12 English
AGM Date 1 page 378.3KB
AGM Information
2016-10-09 English
Chair's Letter 3 pages 456.6KB
Board/Management Information
2016-09-19 English
Preliminary Final Report 48 pages 1.6MB
Annual Report
2016-08-24 English
Lapse and Forfeit of Unlisted Conditional Performance Rights 1
Regulatory Filings
2016-08-22 English
Clinuvel Newsletter 4 pages 613.8KB
Management Reports
2016-08-15 English
Becoming a substantial holder 3 pages 180.2KB
Major Shareholding Notification
2016-08-09 English
Becoming a substantial holder 3 pages 519.8KB
Regulatory Filings
2016-08-09 English
Change of Director's Interest Notice x 4 8 pages 1.1MB
Director's Dealing
2016-08-04 English
Appendix 3B 13 pages 606.8KB
Capital/Financing Update
2016-08-03 English
Clinuvel completes combination therapy pre-clinical study 3 pages 553.0KB
Regulatory Filings
2016-08-02 English
Appendix 4C - quarterly 5 pages 159.4KB
Interim / Quarterly Report
2016-07-28 English
FDA accept SCENESSE clinical data package for NDA submission 3 pages 597.3KB
Regulatory Filings
2016-07-17 English
FDA awards SCENESSE Fast Track designation for EPP treatment 3 pages 101.9KB
Capital/Financing Update
2016-07-05 English
SCENESSE launched in Europe 2 pages 550.3KB
Capital/Financing Update
2016-06-21 English
Clinuvel joins Nasdaq international Designation 2 pages 547.0KB
Regulatory Filings
2016-06-01 English
SCENESSE Treatment in Europe 2 pages 552.1KB
Regulatory Filings
2016-05-17 English
Appendix 4C - quarterly 5 pages 159.2KB
Interim / Quarterly Report
2016-04-28 English
Change in substantial holding 6 pages 1.2MB
Major Shareholding Notification
2016-04-10 English
Clinuvel Newsletter 3 pages 685.3KB
Capital/Financing Update
2016-04-04 English
NICE Highly Specialised Technology workshop reviews SCENESSE 2 pages 563.0KB
Regulatory Filings
2016-03-23 English
Change in substantial holding 2 pages 37.3KB
Major Shareholding Notification
2016-03-17 English
Appendix 3B 12 pages 620.8KB
Share Issue/Capital Change
2016-03-17 English
s.708A Notice 1 page 63.1KB
Capital/Financing Update
2016-03-17 English
Clinuvel Placement 2 pages 453.7KB
Capital/Financing Update
2016-03-14 English
Clinuvel accredits first European EPP expert centres 2 pages 453.9KB
Regulatory Filings
2016-03-14 English
Change in substantial holding 8 pages 1.1MB
Regulatory Filings
2016-03-14 English
Trading Halt 2 pages 481.2KB
Capital/Financing Update
2016-03-10 English
Appendix 4D and Half Year Report 12 pages 314.7KB
Interim / Quarterly Report
2016-02-18 English
Clinuvel brief on European commercialisation 2 pages 102.3KB
Capital/Financing Update
2016-02-15 English
US FDA orphan designation received for cutaneous porphyrias 2 pages 119.7KB
Regulatory Filings
2016-02-11 English
Presentation to international porphyria patient group 25 pages 1.8MB
Investor Presentation
2016-02-07 English
Appendix 4C - quarterly 5 pages 158.8KB
Interim / Quarterly Report
2016-01-27 English
Change in substantial holding 6 pages 1.3MB
Regulatory Filings
2016-01-24 English
CEO Brief 3 pages 275.0KB
Management Reports
2016-01-19 English
Change in substantial holding 3 pages 219.8KB
Major Shareholding Notification
2016-01-17 English